Italy’s suspension of a distinct batch was tied to a person in Sicily who died after receiving his shot. It’s unclear whether or not a blood clot was concerned.
Greater than 142,000 individuals in Denmark, which has a inhabitants of about six million, have been injected with the vaccine produced by AstraZeneca.
The Danish minister of well being, Magnus Heunicke, said on Twitter that it’s “presently not potential to conclude whether or not there’s a connection.” He added. “We acted early, it must be totally investigated.”
Denmark had already scaled again the goal for ending its immunization marketing campaign partially due to delays in deliveries. The security pause will delay it additional.
AstraZeneca’s vaccine got here beneath scrutiny over potential questions of safety final yr whereas it was being examined in scientific trials. Two vaccinated volunteers in Britain developed neurological signs in keeping with transverse myelitis, an inflammatory syndrome that impacts the spinal twine and is usually brought on by viral infections.
These issues briefly shut down world trials of the vaccine, however investigations in the end discovered no proof linking the signs to the vaccine. One of many individuals who fell sick was later discovered to have an undiagnosed case of a number of sclerosis.
Greater than 70 nations have since licensed the vaccine, with the notable exception of america, the place regulators are ready on information from a big scientific trial there anticipated within the subsequent few weeks. A choice from the Meals and Drug Administration on whether or not to authorize AstraZeneca’s vaccine is probably going greater than a month away.
Essentially the most in depth real-world information on the vaccine’s security comes from Britain, which had administered 9.7 million doses via final month. The British drug regulator, the Medicines and Healthcare Merchandise Regulatory Company, stated “the quantity and nature of suspected hostile reactions reported to this point should not uncommon compared to different varieties of routinely used vaccines.”
Rebecca Robbins reported from Bellingham, Wash., and Thomas Erdbrink from Amsterdam. Jason Horowitz and Emma Bubola contributed reporting from Italy, Benjamin Mueller from London and Denise Grady from New York.